Impact of neoadjuvant chemotherapy on lymphocytes and co-inhibitory B7-H4 molecule in gastric cancer: low B7-H4 expression associates with favorable prognosis

Tumor Biology

Volumn 35, Issue 12, 2014, Pages 11837-11843

  Maskey, Ninu ^a   Li, Kai ^a   Hu, Min ^a   Xu, Zhigao ^a   Peng, Chunwei ^a   Yu, Fang ^a   Cao, Hong ^a   Chen, Jiamei ^a   Li, Yan ^a   Yang, Guifang ^a  

^a WUHAN UNIVERSITY   (China)

Author keywords

B7 H4; CD4; CD8; Gastric cancer; Neoadjuvant chemotherapy; Tumor infiltrating lymphocytes

Indexed keywords

ANTINEOPLASTIC AGENT; V SET DOMAIN CONTAINING T CELL ACTIVATION INHIBITOR 1; VTCN1 PROTEIN, HUMAN;

ADJUVANT THERAPY; ADULT; AGED; CANCER GRADING; CANCER STAGING; FEMALE; GENE EXPRESSION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; LYMPHOCYTE; LYMPHOCYTE SUBPOPULATION; MALE; METABOLISM; METASTASIS; MIDDLE AGED; MORTALITY; PHENOTYPE; PROGNOSIS; STOMACH NEOPLASMS; TUMOR ASSOCIATED LEUKOCYTE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE SUBSETS; LYMPHOCYTES; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM GRADING; NEOPLASM METASTASIS; NEOPLASM STAGING; PHENOTYPE; PROGNOSIS; STOMACH NEOPLASMS; V-SET DOMAIN-CONTAINING T-CELL ACTIVATION INHIBITOR 1;

EID: 84925286225     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-2410-2     Document Type: Article

References (27)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–917.
2. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;24(14):2137–50.
3. Zou XN, Duan JJ, Huangfu XM, Chen WQ, Zhao P. Analysis of stomach cancer mortality in the national retrospective sampling survey of death causes in China, 2004–2005. Zhonghua Yu Fang Yi Xue Za Zhi. 2010;44(5):390–7.
4. Lin Y, Ueda J, Kikuchi S, Totsuka Y, Wei WQ, Qiao YL, et al. Comparative epidemiology of gastric cancer between Japan and China. World J Gastroenterol. 2011;17(39):4421–8.
5. Schuhmacher C, Reim D, Novotny A. Neoadjuvant treatment for gastric cancer. J Gastric Cancer. 2013;13(2):73–8.
6. Dikken JL, van de Velde CJ, Coit DG, Shah MA, Verheji M, Cats A. Treatment of resectable gastric cancer. Ther Adv Gastroenterol. 2012;5(1):49–69.
7. Bozzetti F, Gianotti L, Braga M, Di Carlo V, Mariani L. Postoperative complications in gastrointestinal cancer patients: the joint role of the nutritional status and the nutritional support. Clin Nutr. 2007;26(6):698–709.
8. Mezhir JJ, Tang LH, Coit DG. Neoadjuvant therapy of locally advanced gastric cancer. J Surg Oncol. 2010;101(4):305–14.
9. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11–20.
10. Li ZY, Koh CE, Bu ZD, Wu AW, Zhang LH, Wu XJ, et al. Neoadjuvant chemotherapy with FOLFOX: improved outcomes in Chinese patients with locally advanced gastric cancer. J Surg Oncol. 2012;105(8):793–9.
11. Lorenzen S, Blank S, Lordick F, Siewert JR, Ott K. Prediction of response and prognosis by a score including only pretherapeutic parameters in 410 neoadjuvant treated gastric cancer patients. Ann Surg Oncol. 2012;19(7):2119–27.
12. Zamarron BF, Chen W. Dual roles of immune cells and their factors in cancer development and progression. Int J Biol Sci. 2011;7(5):651–8.
13. Sica GL, Choi IH, Zhu G, Tamada K, Wang SD, Tamura H, et al. B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. Immunity. 2003;18(6):849–61.
14. Mugler KC, Singh M, Tringler B, Torkko KC, Liu W, Papkoff J, et al. B7-H4 expression in a range of breast pathology: correlation with tumor T-cell infiltration. Appl Immunohistochem Mol Morphol. 2007;15(4):363–70.
15. Chen LJ, Sun J, Wu HY, Zhou SM, Tan Y, Tan M, et al. B7-H4 expression associates with cancer progression and predicts patient's survival in human esophageal squamous cell carcinoma. Cancer Immunol Immunother. 2011;60(7):1047–55.
16. Liang M, Li JY, Wang DD, Li SC, Sun Y, Sun TW, et al. T-cell infiltration and expressions of T lymphocyte co-inhibitory B7-H1 and B7-H4 molecules among colorectal cancer patients in northeast China’s Heilongjiang Province. Tumor Biol. 2014;35(1):55–60.
17. Zhang L, Wu H, Lu D, Li G, Sun C, Song H, et al. The costimulatory molecule B7-H4 promote tumor progression and cell proliferation through translocating into nucleus. Oncogene. 2013;32(46):5347–58.
18. Arigami T, Uenosono Y, Ishigami S, Hagihara T, Haraguchi N, Natsugoe S. Clinical significance of the B7-H4 coregulatory molecule as a novel prognostic marker in gastric cancer. World J Surg. 2011;35(9):2051–7.
19. Jiang JT, Zhu YB, Wu CP, Shen YP, Wei WX, Chen L, et al. Tumor expression of B7-H4 predicts poor survival of patients suffering from gastric cancer. Cancer Immunol Immunother. 2010;59(11):1707–14.
20. Ladoire S, Mignot G, Dabakuyo S, Arnould L, Apetoh L, Rebe C, et al. In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival. J Pathol. 2011;224(3):389–400.
21. Tsuchikawa T, Md MM, Yamamura Y, Shichinohe T, Hirano S, Kondo S. The immunological impact of neoadjuvant chemotherapy on the tumor microenvironment of esophageal squamous cell carcinoma. Ann Surg Oncol. 2012;19(5):1713–9.
22. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand. 1965;64:31–49.
23. Washington K. 7th edition of the AJCC cancer staging manual: stomach. Ann Surg Oncol. 2010;17(12):3077–9.
24. Seliger B, Marincola FM, Ferrone S, Abken H. The complex role of B7 molecules in tumor immunology. Trends Mol Med. 2008;14(12):550–9.
25. Shurin MR. Dual role of immunomodulation by anticancer chemotherapy. Nat Med. 2013;19(1):20–2.
26. Galluzzi L, Senovilla L, Zitvogel L, Kroemer G. The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov. 2012;11(3):215–33.
27. Rahir G, Moser M. Tumor microenvironment and lymphocyte infiltration. Cancer Immunol Immunother. 2012;61(6):751–9.